News Focus
News Focus
Followers 76
Posts 6475
Boards Moderated 0
Alias Born 05/25/2021

Re: sukus post# 725791

Sunday, 10/13/2024 11:24:13 AM

Sunday, October 13, 2024 11:24:13 AM

Post# of 817892
Sky has mentioned many times: combination is the king.

To tackle all these tumor-associated immunosuppressive characteristics, combination is the way. IMO, NWBO has achieved the most crucial milestone in treating cancer: triggering massive and sustainable t cell infiltration into tumor sites. The next step is to take care of immunosuppresion of different types. Of course, adding CYT107 to increase t cell counts should be included in the future trials too.

Guess which company has most of the inhibitors can be used in future clinical trials to tackle immunosuppresion.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News